Novo Nordisk launched Wegovy in India in June 2025, cut prices by up to 37% in November 2025, and partnered with Emcure to bring another semaglutide brand to market
According to GEN (Genetic Engineering & Biotechnology News), here are the Top 10 CDMOs of 2025, ranked by 2024 revenues: 1 Lonza ~$8.1B 2 Thermo Fisher Scientific ~$7.0B 3 Catalent (part of Novo Holdings) ~$4.4B 4 Samsung Biologics ~$3.3B 5 WuXi Biologics ~$2.6B 6 Siegfried ~$1.6B 7 FUJIFILM Biotechnologies ~$1.5B 8 Boehringer Ingelheim (Bioxcellence R&D Institute) ~$1.4B 9 Recipharm ~$958M MilliporeSigma / Merck Group ~$836M Key takeaway: The rise of biologics is transforming pharma manufacturing
The picture is much different on Trustpilot, where Henry has more than 4,500 reviews that result in an average rating of 4.7 stars
Timeline remains uncertain Health Canada's target timeline for initial review of a generic drug is 180 days, and the agency says it is on track to meet review targets for generic semaglutide submissions [Source: cbc.ca/news/health/generic-ozempic-canada-waiting-9.7142339]
Ung vi nhiu nc Anh ch c th tham kho thm cc sn phm Glutathione ang c ti EU Store la chn sn phm ph hp vi nhu cu ca mnh
How can I manage other side effects of Ozempic
.webp)
